Which pediatric XXXX @entity1 do not require pelvic imaging?

@entity1 @entity811 @entity174 @entity772 @entity158 @entity1344 @entity85 @entity130
BACKGROUND: This study aimed to develop a tool in identifying traumatized @entity1 at low risk of @entity174 and to determine the sensitivity of this low-risk model for @entity174 . We hypothesized that the proportion of @entity1 without predictors with @entity174 is less than 1%. METHODS: This is a retrospective @entity130 registry analysis of previously healthy @entity1 1 year to 17 years old presenting to the pediatric emergency department with @entity130 . Postulated predictors of @entity174 on radiograph or computed tomography included @entity158 /abnormal examination result of the pelvis/hip, @entity85 , @entity811 , abdominal @entity158 /tenderness, Glasgow @entity772 Scale (GCS) score of 13 or lower, and @entity1344 . We used multivariable logistic regression to identify independent predictors of @entity174 . RESULTS: Of 1,121 eligible @entity1 (mean [SD] age, 8.5 [4.6] years), 87 (7.8%) had @entity174 . Independent predictors included @entity158 /abnormal examination result of the pelvis/hip (odds ratio [OR], 16.7; 95% confidence interval [CI], 9.6-29.1), @entity811 (OR, 6.6; 95% CI, 3.0-14.6), @entity85 (OR, 5.9; 95% CI, 3.1-11.3), GCS score of 13 or lower (OR, 2.4; 95% CI, 1.3-4.3), and @entity1344 (OR, 3.4; 95% CI, 1.7-6.9). One of 590 @entity1 (0.2%; 95% CI, 0-0.5%) without predictors had @entity174 versus 86 (16.2%) of 531 in those with one or more predictors (OR, 119; 95% CI, 16.6-833). One of 87 @entity1 with @entity174 had no predictors (1.1%; 95% CI, 0-3%). When assuming a 100% radiography rate, this tool saves 53% pelvic radiographs. CONCLUSION: @entity1 with multiple @entity130 without @entity158 /abnormal examination result of the pelvis/hip, @entity85 , @entity811 , abdominal @entity158 /tenderness, GCS score of 13 or lower, or @entity1344 constitute a low-risk population for @entity174 , with less than 0.5% risk rate. This population does not require routine pelvic imaging. LEVEL OF EVIDENCE: Therapeutic study, level IV.
